Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 08 May 2019 Planned number of patients changed to 30.
- 20 Mar 2019 Status changed from recruiting to active, no longer recruiting.
- 18 Dec 2018 Planned End Date changed from 1 Mar 2024 to 1 Mar 2023.